Opus Genetics Presents Positive Clinical Data for OPGx-BEST1 and OPGx-LCA5 Gene Therapies

Opus Genetics presented positive clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at the Retina in Rio 2026 conference. The OPGx-BEST1 Phase 1/2 trial showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose cohort, with new analyses linking retinal structure to visual function. The OPGx-LCA5 Phase 1/2/3 trial demonstrated sustained improvements in visual acuity and light sensitivity through 24 months in adults and encouraging results in pediatric participants through six months. The company expects to initiate dosing for the Phase 3 OPGx-LCA5 clinical trial in the fourth quarter of 2026.